Breast Cancer 2010,17(3):190–198.PubMed 64. Lewis JD, Chagpar AB, Shaughnessy EA, Nurko J, McMasters K, Edwards MJ: Excellent

outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. Cancer 2010,116(10):2307–2315.PubMed 65. Loesch D, Greco FA, Senzer NN, Burris HA, Hainsworth JD, Jones S, Vukelja SJ, Sandbach J, Holmes F, Sedlacek S, Pippen J, Lindquist D, McIntyre selleck products K, Blum JL, Modiano MR, Boehm KA, Zhan F, Asmar L, Robert N: Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast Cancer. J Clin Oncol 2010,28(18):2958–2965.PubMed 66. Love RR, Duc NB, Allred DC, Binh NC, Dinh NV, Kha NN, Thuan TV, Mohsin SK, le Roanh D, Khang HX, Tran TL, Quy TT, Thuy NV, Thé PN, Cau TT, Tung ND, Huong DT, le Quang M, Hien NN, Thuong L, Shen TZ, Xin Y, Zhang Q, Havighurst TC, Yang YF, Hillner BE, DeMets DL: Oophorectomy and Tamoxifen Adjuvant Therapy in Premenopausal Vietnamese

and Chinese Women With Operable Breast Cancer. J Clin Oncol 2002,20(10):2559–2566.PubMed 67. Mamounas EPBJ, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N: Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP Selleck MK-8776 Avelestat (AZD9668) B-28. J Clin Oncol 2005,23(16):3686–3696.PubMed 68. Martin M, Segui MA, Anton A, Ruiz A, Ramos M, Adrover E, Aranda I, Rodriguez Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, Martinez Del Prado P,

Ruiz Borrego M, Zaluski J, Arcusa A, Muñoz M, Lopez Vega JM, Mel JR, Munarriz B, Llorca C, Jara C, Alba E, Florian J, Li J, Lopez Garcia Asenjo JA, Saez A, Rios MJ, Almenar S, Peiro G, Lluch A, GEICAM 9805 Investigators: Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. N Engl J Med 2010,363(23):2200–2210.PubMed 69. Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munarriz B, Rodriguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators: Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer. J Natl Cancer Inst 2008,100(11):805–814.PubMed 70.